论文部分内容阅读
目的:观察并分析尤瑞克林联合依达拉奉对急性脑梗死患者脑血管储备能力的改良与神经功能保护作用。方法:选取2012年12月~2016年8月我院收治的90例急性脑梗死患者为研究对象,按随机法原则分为观察组和对照组,每组45例。两组患者入院后给予抗血小板聚集、改善微循环、降血脂、降血压、降血糖及抗感染等常规治疗,对照组在常规治疗基础上给予依达拉奉治疗,观察组在对照组的基础上加用尤瑞克林治疗。比较两组患者治疗前后日常生活活动能力(ADL)评分、美国国立卫生研究卒中量表(NIHSS)评分。比较治疗前和治疗14天后的颅内血液流变学指标、水肿面积和不良反应发生情况。结果:观察组患者治疗总有效率明显高于对照组,差异具有统计学意义。治疗后两组患者NIHSS评分、ADL评分和水肿面积明显改善,且与对照组相比,观察组患者ADL评分明显升高,而NIHSS评分和水肿面积显著减少,差异均具有统计学意义。治疗后观察组全血高切黏度、纤维蛋白原、血浆黏度等指标显著低于对照组,差异具有统计学意义。两组患者缺全血低切黏度差异不具有统计学意义。两组患者不良反应发生率比较无明显差异,不具有统计学意义。结论:尤瑞克林联合依达拉奉治疗急性脑梗死,能够改善患者脑血管储备能力,同时清除体内自由基,对缺血后再灌注引起的神经损伤具有保护作用,改善患者日常生活能力,值得临床推广使用。
Objective: To observe and analyze the effect of uracil combined with edaravone on cerebral vascular reserve and neurological protection in patients with acute cerebral infarction. Methods: Ninety patients with acute cerebral infarction admitted to our hospital from December 2012 to August 2016 were selected as study object and divided into observation group and control group according to the principle of randomization, with 45 cases in each group. Two groups of patients were given anti-platelet aggregation after admission to improve the microcirculation, hypolipidemic, antihypertensive, hypoglycemic and anti-infective and other conventional treatment, the control group on the basis of conventional treatment with edaravone treatment, the observation group in the control group based On the use of uricin treatment. The activities of daily living (ADL) before and after treatment were compared between the two groups, and the National Institutes of Health Stroke Scale (NIHSS) score. The intracranial hemorheology, edema area and adverse reactions before and 14 days after treatment were compared. Results: The total effective rate of observation group was significantly higher than that of control group, the difference was statistically significant. After treatment, the NIHSS score, ADL score and edema area of the two groups were significantly improved. Compared with the control group, the ADL score of the observation group was significantly increased, while the NIHSS score and edema area were significantly reduced, the differences were statistically significant. After treatment, the observation group of high blood viscosity, fibrinogen, plasma viscosity and other indicators were significantly lower than the control group, the difference was statistically significant. There was no significant difference between the two groups in the whole blood low shear viscosity. There was no significant difference between the two groups in the incidence of adverse reactions, not statistically significant. Conclusion: The combination of uracil and edaravone in patients with acute cerebral infarction can improve the ability of cerebrovascular reserve, eliminate free radicals in the body, protect the nerve injury induced by ischemia and reperfusion, improve the daily living ability, It is worth to promote clinical use.